Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hakan Harputluoglu

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Lancet (London, England)|September 17, 2017
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trialDaniel P Petrylak, Ronald de Wit, Kim N Chi, et al.
The Lancet. Oncology|November 23, 2019
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trialDaniel P Petrylak, Ronald de Wit, Kim N Chi, et al.
Head & Neck|April 21, 2023
Major and minor salivary gland cancers: A multicenter retrospective studyMuhammet Bekir Hacioglu, Bulent Erdogan, Murat Bardakcı, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Lancet (London, England)|September 17, 2017
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trialDaniel P Petrylak, Ronald de Wit, Kim N Chi, et al.
The Lancet. Oncology|November 23, 2019
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trialDaniel P Petrylak, Ronald de Wit, Kim N Chi, et al.
Head & Neck|April 21, 2023
Major and minor salivary gland cancers: A multicenter retrospective studyMuhammet Bekir Hacioglu, Bulent Erdogan, Murat Bardakcı, et al.
Pageof 4